Premium
Combination Therapy for Osteoporosis with Estrogen, Fluoride, and Calcium *
Author(s) -
ALOIA JOHN F.,
ZANZI ITALO,
VASWANI ASHOK,
ELLIS KENNETH,
COHN STANTON H.
Publication year - 1982
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.1982.tb03698.x
Subject(s) - medicine , osteoporosis , calcium , combination therapy , estrogen , postmenopausal osteoporosis , fluoride , bone mineral , estrogen replacement therapy , urology , endocrinology , inorganic chemistry , chemistry
Nine women with postmenopausal spinal osteoporosis were treated with combination therapy consisting of estrogen, fluoride, and calcium. Their data were compared with those of a control group treated with fluoride and calcium without estrogen. Bone mass was measured about every six months by photon absorptiometry [bone mineral content/bone width (BMC/BW)] and total‐body neutron activation analysis [total‐body calcium (TB Ca)]. Time‐trend analysis revealed positive slopes for TB Ca ( P = 0.002) and BMC/BW ( P = N.S.) for the combination therapy group. The change in BMC/BW in the combination therapy group was significantly different from the response in the fluoride‐calcium group. These data suggest that combination therapy may be successful in increasing bone mass in postmenopausal osteoporosis. A clinical trial to establish efficacy and examine risk/benefit ratios should be performed.